Chhipa et al. [89] showed that AMPK inhibitor (bafilomycin) decreased the viability of glioblastoma stem cells (GSCs), while Pang et al. [100] found that anti-PD1 antibody synergistically blocked the HIF1α-LGMN axis with anti-PD1 therapy in glioblastoma. This evidence concerns the gene PRKAA1 and glioblastoma.